For the bionic pancreas to win FDA approval, it will need to prove that the novel aspects of the treatment are safe and effective. Recently, a team of researchers at the Massachusetts General Hospital Diabetes Center in Boston conducted a trial that focused exclusively on the automated delivery of glucagon to see if the treatment could prevent hypoglycemia and generally keep study participants in a desired range of blood sugar control.

Read more